ATE485818T1 - Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren - Google Patents

Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren

Info

Publication number: ATE485818T1
Authority: AT; Austria
Prior art keywords: cholesterol; ezetimibe; associated tumor; methods; malignant tumors
Prior art date: 2002-07-30

Application number

AT03772067T

Other languages

English (en)

Inventor

Carl Schaffner

Keith Solomon

Michael Freeman

Original Assignee

Karykion Inc

Childrens Medical Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-30

Filing date

2003-07-30

Publication date

2010-11-15

2003-07-30 Application filed by Karykion Inc, Childrens Medical Center filed Critical Karykion Inc

2010-11-15 Application granted granted Critical

2010-11-15 Publication of ATE485818T1 publication Critical patent/ATE485818T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 6
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title abstract 6
229960000815 ezetimibe Drugs 0.000 title abstract 5
239000000203 mixture Substances 0.000 title abstract 5
238000000034 method Methods 0.000 title abstract 2
230000003211 malignant effect Effects 0.000 title 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 10
235000012000 cholesterol Nutrition 0.000 abstract 5
230000002265 prevention Effects 0.000 abstract 3
229940122502 Cholesterol absorption inhibitor Drugs 0.000 abstract 2
MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 abstract 2
229930182480 glucuronide Natural products 0.000 abstract 2
-1 phenolic glucuronide Chemical class 0.000 abstract 2
DPZUDTYEZMUJDW-GMUMFXLYSA-N (1r)-7-(4-chlorophenyl)-2-(4-fluorophenyl)-7-hydroxy-1-(4-hydroxyphenyl)-2-azaspiro[3.5]nonan-3-one Chemical compound C1=CC(O)=CC=C1[C@@H]1C2(CCC(O)(CC2)C=2C=CC(Cl)=CC=2)C(=O)N1C1=CC=C(F)C=C1 DPZUDTYEZMUJDW-GMUMFXLYSA-N 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
229940127084 other anti-cancer agent Drugs 0.000 abstract 1
IMNTVVOUWFPRSB-JWQCQUIFSA-N sch-48461 Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(OC)=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 IMNTVVOUWFPRSB-JWQCQUIFSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT03772067T 2002-07-30 2003-07-30 Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren ATE485818T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39969002P	2002-07-30	2002-07-30
PCT/US2003/023764 WO2004010948A2 (en)	2002-07-30	2003-07-30	Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
US10/630,578 US6933292B2 (en)	2002-07-30	2003-07-30	Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors

Publications (1)

Publication Number	Publication Date
ATE485818T1 true ATE485818T1 (de)	2010-11-15

Family

ID=32511171

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03772067T ATE485818T1 (de)	2002-07-30	2003-07-30	Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren

Country Status (10)

Country	Link
US (3)	US6933292B2 (de)
EP (1)	EP1545479B1 (de)
JP (1)	JP2006501205A (de)
CN (1)	CN1678296A (de)
AT (1)	ATE485818T1 (de)
AU (1)	AU2003254261B2 (de)
CA (1)	CA2493614C (de)
DE (1)	DE60334711D1 (de)
NZ (1)	NZ538498A (de)
WO (1)	WO2004010948A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2011802A3 (de)	2001-04-27	2009-04-15	Kyowa Hakko Kirin Co., Ltd.	Monoklonaler Antikörper gegen CD40
GB0215579D0 (en)	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds
ATE485818T1 (de) *	2002-07-30	2010-11-15	Karykion Inc	Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
CN1874780A (zh) *	2003-09-26	2006-12-06	福布斯梅迪泰克公司	抑制多抗药性基因表达并抑制由该基因表达导致的蛋白质产生从而提高化学治疗剂治疗癌症有效性的方法
CA2550215A1 (en)	2003-12-23	2005-07-07	Astrazeneca Ab	Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
US8361999B2 (en)	2005-04-04	2013-01-29	Pontificia Universidad Catolica De Chile	Methods of treating cholesterol gallstone disease with ezetimibe
SA06270191B1 (ar)	2005-06-22	2010-03-29	استرازينيكا ايه بي	مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR060623A1 (es)	2006-04-27	2008-07-02	Astrazeneca Ab	Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20070275052A1 (en) *	2006-05-24	2007-11-29	Glenmark Pharmaceuticals Limited	Pharmaceutical compositions containing sterol inhibitors
US20090208448A1 (en) *	2008-02-15	2009-08-20	Solomon Keith R	Inhibition of angiogenesis
US9034863B2 (en)	2008-09-02	2015-05-19	The Board Of Trustees Of The University Of Illinois	Compositions and methods for inhibiting entry of a hepatic virus
US8673288B2 (en) *	2008-09-02	2014-03-18	The Board Of Trustees Of The University Of Illinois	Compositions and methods for inhibiting entry of a hepatic virus
WO2015065505A1 (en) *	2013-10-29	2015-05-07	Duke University	Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
WO2021094933A1 (en) *	2019-11-12	2021-05-20	University Of South Africa	Ezetimibe and curcumin for use in cancer treatment
WO2022087437A1 (en) *	2020-10-22	2022-04-28	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Methods of treatment
CN115364094A (zh) *	2021-05-19	2022-11-22	南京大学	伊折麦布在制备抗肿瘤药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE637389A (de)	1962-09-13
US3622437A (en) *	1969-05-09	1971-11-23	Gen Dynamics Corp	Composite buoyancy material
EP0002097B1 (de)	1977-08-22	1981-08-05	Imperial Chemical Industries Plc	Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
DE3046719C2 (de)	1980-12-11	1983-02-17	Klinge Pharma GmbH, 8000 München	1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en)	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US4719207A (en) *	1984-06-25	1988-01-12	Yamanouchi Pharmaceutical Co., Ltd.	CNS active substituted azetidinone compounds
US4639420A (en) *	1984-11-21	1987-01-27	Schaffner Carl P	Method for the immunoanalysis of cholesterol epoxides
GB2196003A (en)	1986-09-11	1988-04-20	Nat Res Dev	Iodo-and bromo-tamoxifen derivatives
ES2189784T3 (es)	1989-07-07	2003-07-16	Endorech Inc	Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
TW223059B (de) *	1991-07-23	1994-05-01	Schering Corp
AU680818B2 (en)	1992-05-21	1997-08-14	Endorecherche Inc.	Improved antiandrogens
FR2697752B1 (fr)	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
LT3595B (en) *	1993-01-21	1995-12-27	Schering Corp	Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) *	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5972383A (en)	1994-03-02	1999-10-26	Eli Lilly And Company	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5613460A (en) *	1994-08-31	1997-03-25	Newport News Shipbuilding And Dry Dock Company	Submersible vessel external load mounting system
US6395770B1 (en)	1995-10-26	2002-05-28	Baker Norton Pharmaceuticals, Inc.	Method and compositions for administering taxanes orally to human patients
US5919815A (en) *	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
JPH10179086A (ja) *	1996-11-05	1998-07-07	Riken Vitamin Co Ltd	植物ステロールを含有する油溶化液及び飲食物並びにその製造方法
US6245352B1 (en)	1999-04-27	2001-06-12	Eli Lilly And Company	Pharmaceutical formulation
US6380405B1 (en)	1999-09-13	2002-04-30	Nobex Corporation	Taxane prodrugs
AU3822701A (en) *	2000-02-17	2001-08-27	Merck & Co., Inc.	Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
US20020013334A1 (en) *	2000-06-15	2002-01-31	Robl Jeffrey A.	HMG-CoA reductase inhibitors and method
WO2002020457A1 (en) *	2000-09-06	2002-03-14	Merck & Co., Inc.	Dihydroxy open-acid salt of simvastatin
AU2001292874B2 (en)	2000-09-27	2006-06-15	Merck & Co., Inc.	Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
US6534540B2 (en) *	2000-10-06	2003-03-18	George Kindness	Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
IL156552A0 (en) *	2000-12-21	2004-01-04	Aventis Pharma Gmbh	Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
SI1354888T1 (sl) *	2000-12-28	2009-10-31	Kissei Pharmaceutical	Glukopiranoziloksipirazolni derivati in njihova uporaba v zdravilih
SI1429756T1 (sl) *	2001-09-21	2007-02-28	Schering Corp	Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
ATE485818T1 (de) *	2002-07-30	2010-11-15	Karykion Inc	Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
US20040145092A1 (en) *	2003-01-24	2004-07-29	Mccollum Robert P.	Method of making a composite molded article
US7263028B2 (en) *	2003-10-09	2007-08-28	United States Of America As Represented By The Secretary Of The Navy	Composite acoustic attenuation materials

2003
- 2003-07-30 AT AT03772067T patent/ATE485818T1/de not_active IP Right Cessation
- 2003-07-30 JP JP2004525042A patent/JP2006501205A/ja active Pending
- 2003-07-30 CA CA2493614A patent/CA2493614C/en not_active Expired - Lifetime
- 2003-07-30 AU AU2003254261A patent/AU2003254261B2/en not_active Ceased
- 2003-07-30 WO PCT/US2003/023764 patent/WO2004010948A2/en not_active Ceased
- 2003-07-30 US US10/630,578 patent/US6933292B2/en not_active Expired - Lifetime
- 2003-07-30 EP EP03772067A patent/EP1545479B1/de not_active Expired - Lifetime
- 2003-07-30 CN CNA038205904A patent/CN1678296A/zh active Pending
- 2003-07-30 DE DE60334711T patent/DE60334711D1/de not_active Expired - Lifetime
- 2003-07-30 NZ NZ538498A patent/NZ538498A/en not_active IP Right Cessation
2005
- 2005-05-12 US US11/128,140 patent/US7098198B2/en not_active Expired - Fee Related
2006
- 2006-07-13 US US11/485,773 patent/US7449453B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20070037755A1 (en)	2007-02-15
AU2003254261A1 (en)	2004-02-16
CN1678296A (zh)	2005-10-05
NZ538498A (en)	2009-02-28
CA2493614C (en)	2011-09-13
US7098198B2 (en)	2006-08-29
US20050209167A1 (en)	2005-09-22
JP2006501205A (ja)	2006-01-12
EP1545479A2 (de)	2005-06-29
US20040116358A1 (en)	2004-06-17
EP1545479A4 (de)	2007-10-24
US6933292B2 (en)	2005-08-23
WO2004010948A2 (en)	2004-02-05
EP1545479B1 (de)	2010-10-27
WO2004010948A3 (en)	2004-07-01
CA2493614A1 (en)	2004-02-05
DE60334711D1 (de)	2010-12-09
US7449453B2 (en)	2008-11-11
AU2003254261B2 (en)	2008-04-17

Legal Events

Date	Code	Title	Description
2011-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60334711D1 (de)	2010-12-09	Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
DE60031268D1 (de)	2006-11-23	Verfahren und zusammansetzung zur behandlung von krebs
BR0109517A (pt)	2006-08-29	métodos e composições sinérgicas para tratar o cáncer
YU59103A (sh)	2006-05-25	Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
EA199900137A1 (ru)	1999-06-24	Замещенные пиридины в качестве избирательных ингибиторов циклооксигеназы-2
ATE367158T1 (de)	2007-08-15	Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen
ATE268179T1 (de)	2004-06-15	Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
DE69127175D1 (de)	1997-09-11	Antisens-Oligonukleotide zur Behandlung von Krebs
DE69830072D1 (de)	2005-06-09	Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE602004025726D1 (de)	2010-04-08	Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
ATE219363T1 (de)	2002-07-15	Lösliche prodrugs von paclitaxel
DE60234577D1 (de)	2010-01-14	Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
DE60118547D1 (de)	2006-05-18	Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
ATE260282T1 (de)	2004-03-15	Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE170077T1 (de)	1998-09-15	Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
DE60121440D1 (de)	2006-08-24	Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
IL128568A0 (en)	2000-01-31	Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
EP1427418A4 (de)	2004-11-17	Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel und behandlungsverfahren
ATE283044T1 (de)	2004-12-15	Compactin zur behandlung von entzündungen
DE60230155D1 (de)	2009-01-15	Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
DE59508366D1 (de)	2000-06-21	Verwendung von boswelliasäure zur behandlung von hirntumoren
WO2000061141A3 (en)	2001-03-01	Methods and compositions for enhancing delivery of therapeutic agents to tissues
DE60005952T8 (de)	2004-11-04	Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten
BR0211436A (pt)	2004-07-13	Método e composição para tratamento de câncer
ATE315387T1 (de)	2006-02-15	Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz